By Josh White
Date: Monday 18 Mar 2024
(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.
Director/PDMR Shareholding | 26-Mar-2024 | 15:30 | RNS |
Notice of AGM | 25-Mar-2024 | 13:00 | RNS |
Transfer of Treasury Shares | 22-Mar-2024 | 16:20 | RNS |
Director/PDMR Shareholding | 22-Mar-2024 | 15:36 | RNS |
New Phase III Jemperli data in endometrial cancer | 18-Mar-2024 | 09:30 | RNS |
GlaxoSmithKline scraps sale of old drugs | 05-Dec-2014 | Telegraph |
Glaxo sharpens axe to save £1bn as insurers and ... | 01-Dec-2014 | The Independent |
GSK to cut hundreds of US jobs | 01-Dec-2014 | Telegraph |
Ebola vaccine trials 'encouraging', says GSK | 27-Nov-2014 | Telegraph |
GlaxoSmithKline tops table in effort to get drug... | 17-Nov-2014 | Guardian |
Questor :GlaxoSmithKline | 16-Apr-2014 | Telegraph |
Questor:GlaxoSmithKline | 06-Oct-2011 | Telegraph |
Questor:GlaxoSmithKline | 11-Aug-2011 | Telegraph |
Questor tip: GlaxoSmithKline | 28-Jul-2011 | Telegraph |
Investment Column: GlaxoSmithKline | 27-Jul-2011 | The Independent |
Currency | UK Pounds |
Share Price | 1,708.60p |
Change Today | 3.40p |
% Change | 0.20 % |
52 Week High | 1,713.00 |
52 Week Low | 1,316.00 |
Volume | 7,547,306 |
Shares Issued | 4,144.88m |
Market Cap | £70,819m |
RiskGrade | 129 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 7 |
Buy | 6 |
Neutral | 9 |
Sell | 2 |
Strong Sell | 0 |
Total | 24 |
Latest | Previous | |
---|---|---|
Q4 | Q3 | |
Ex-Div | 22-Feb-24 | 16-Nov-23 |
Paid | 11-Apr-24 | 11-Jan-24 |
Amount | 16.00p | 14.00p |
Time | Volume / Share Price |
17:14 | 750,000 @ 1,709.81p |
17:04 | 13,917 @ 1,706.01p |
17:04 | 13,076 @ 1,706.01p |
17:04 | 549 @ 1,706.01p |
17:03 | 172,458 @ 1,706.01p |
You are here: research